HICOR strives to reduce the human and economic burden of cancer by conducting innovative research in areas that include the financial impact of cancer, cancer outcomes, cost-effectiveness of technologies and treatments, cancer care delivery and cancer policy. Some of our many ongoing projects are described below.
Colony stimulating factor — a naturally occurring substance in the body that helps bone marrow produce red blood cells — is prescribed to patients undergoing chemotherapy treatment that carries a high risk of a serious, life-threatening complication called febrile neutropenia. Studies show that CSF is both overused and underused, exposing patients to unnecessary risk and cost. HICOR is partnering with Columbia University, University of Washington and SWOG Cancer Research Network on a pioneering study to investigate whether a guideline-informed, standing order to administer preventive CSF improves guideline adherence and reduces the incidence of febrile neutropenia. Forty-five clinics across the country are participating in the TrACER Study, which is funded by the Patient-Centered Outcomes Research Institute (PCORI) and the National Cancer Institute’s Community Oncology Research Program.
About 100,000 people in the U.S. are affected by sickle cell disease, a disproportionate percentage of which are black or Hispanic. About one in 13 black or African Americans have sickle cell trait and are at risk for having a child with the disease. The inherited blood disorder leads to many medical complications and shortens the life spans of people affected by about 20-30 years. For people living with the disease, early intervention and access to care are vital for their long-term prognosis, physically and psychologically. HICOR is partnering with NHLBI, Emmes, and University of Washington to develop models that will estimate the clinical and economic benefits of cures for sickle cell disease. The goal is to clarify the potential long-term benefits of promising new curative therapies.